Literature DB >> 34040305

Hyperphosphatemic Tumoral Calcinosis: A Classical Clinico-Radio-Scintigraphic Presentation.

Rimesh Pal1, Ashwin Singh Parihar2, Sanjay Kumar Bhadada1, Bhagwant Rai Mittal2.   

Abstract

Tumoral calcinosis is a rare entity presenting with periarticular calcium deposits, leading to multiple swellings and biochemical hyperphosphatemia and normocalcemia. Skeletal scintigraphy in these cases is helpful by providing a whole-body survey and delineating the common multifocality of this entity. We present the case of a 16-year-old boy with multiple swellings around the knee and elbow joints, having developed over 4 years and diagnosed as tumor calcinosis. Copyright:
© 2021 Indian Journal of Nuclear Medicine.

Entities:  

Keywords:  Bone scan; hyperparathyroidism; metabolic bone disease; methylene diphosphonate

Year:  2021        PMID: 34040305      PMCID: PMC8130691          DOI: 10.4103/ijnm.IJNM_86_20

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


Interesting Image

A 16-year-old boy presented with gradually progressive swellings developing around the knees and right elbow over the past 4 years [Figure 1a and b]. Those over the knees had spontaneously ruptured, extruding chalky-white pasty discharge. In addition, the swellings were causing mechanical hindrance in the knee movements. Investigations revealed normal renal function, normocalcemia, hyperphosphatemia (serum phosphate 8.8 mg/dl), and increased renal tubular reabsorption of phosphate (96%). His fibroblast growth factor-23 (FGF-23) was inappropriately normal for the degree of hyperphosphatemia. Planar radiograph showed patchy areas of heterotopic calcification along the medial aspect of the thighs and the knee joints [Figure 1c and d]. 99mTc-methylene diphosphonate (99mTc-MDP) planar bone scintigraphy followed by hybrid single-photon emission computed tomography with computed tomography (SPECT/CT) showed areas of increased osteoblastic activity in multiple lesions around the right elbow, bilateral knees, and along the medial aspect of both the thighs [Figure 1e-g]. He was diagnosed with having primary hyperphosphatemic tumoral calcinosis. He was placed on a low phosphate diet and started on oral acetazolamide and sevelamer as a phosphate-binding drug. At follow-up, his serum phosphate has come down to 6.4 mg/dl and the lesions have not further increased in size. The surgical excision of the calcified masses surrounding the knees is being contemplated.
Figure 1

Clinical pictures of the patient showing multiple peri-articular discharging swellings in the bilateral knee (a) and elbow (b) joints. Planar radiographs in antero-posterior (c) and lateral (d) views showing patchy heterotopic calcification along medial aspect of bilateral thighs and knee joints. 99mTc-methylene diphosphonate whole-body planar (e) and single photon emission computed tomography with computed tomography (f and g) images showing increased tracer uptake in the areas of heterotopic ossification, corresponding to clinical and radiologic images

Clinical pictures of the patient showing multiple peri-articular discharging swellings in the bilateral knee (a) and elbow (b) joints. Planar radiographs in antero-posterior (c) and lateral (d) views showing patchy heterotopic calcification along medial aspect of bilateral thighs and knee joints. 99mTc-methylene diphosphonate whole-body planar (e) and single photon emission computed tomography with computed tomography (f and g) images showing increased tracer uptake in the areas of heterotopic ossification, corresponding to clinical and radiologic images Hyperphosphatemic tumoral calcinosis presents as a single or multiple painless swellings in the peri-articular region. The biochemical profile is characterized by normal serum calcium and elevated levels of serum phosphate.[1] Plain radiographs of the affected region show cystic lesions with amorphous and multi-lobulated calcifications.[2] It is regarded as an idiopathic entity, in contrast to dystrophic calcification (inflammatory process with normal serum calcium and phosphate) and metastatic calcification (involving visceral organs, with hypercalcemia).[1] Genetic studies have shown the presence of mutations involving GALNT3, FGF-23, and α-KLOTHO genes leading to dysregulation of phosphate metabolism.[1] Skeletal scintigraphy with 99mTc-MDP has a vital role in multiple oncologic and nononcologic, metabolic bone diseases.[345] In a patient with tumoral calcinosis, skeletal scintigraphy provides for a complete skeletal survey, thus delineating all the disease sites in a single study. This becomes important, especially as surgical excision of the lesions is curative. Increased uptake of 99mTc-MDP at the involved sites is due to increased vascularity and osteoblastic activity in the extra-skeletal tissues.[67] In addition to planar scintigraphy, SPECT/CT can improve the lesion visualization, by eliminating overlap from surrounding structures and can also provide valuable anatomic correlation. Positron emission tomography with 18F-fluorodeoxyglucose and CT has also shown to be positive in patients with tumoral calcinosis, likely reflecting sites undergoing active mineralization, and thus an increased glucose metabolism.[8] In addition, the association of tumoral calcinosis with hyperparathyroidism makes imaging with 99mTc-MIBI useful, as it can detect the metabolically active sites as well as the presence of concurrent brown tumors.[910] Tumoral calcinosis is a rare entity that needs accurate diagnosis, eliminating the closely mimicking differentials (such as calcinosis cutis and myositis ossificans) and adequate workup toward the disease extent. Scintigraphic studies play a vital role in this respect and thereby help plan surgical excision as a form of curative treatment.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  10 in total

1.  Intense F-18 FDG accumulation in idiopathic tumoral calcinosis.

Authors:  Chio Okuyama; Takao Kubota; Shigenori Matsushima; Yo Ushijima; Tsunehiko Nishimura
Journal:  Clin Nucl Med       Date:  2009-04       Impact factor: 7.794

2.  Scintigraphic Images of Massive Tumoral Calcinosis.

Authors:  Yiyan Liu
Journal:  Clin Nucl Med       Date:  2016-06       Impact factor: 7.794

3.  Case of tumoral calcinosis on images: a rare clinicopathological entity.

Authors:  Harpreet Singh; Richa Handa; Zeeshan Arshad; Eric G Hoover
Journal:  BMJ Case Rep       Date:  2017-10-23

Review 4.  Diagnostic bone scanning in oncology.

Authors:  A Z Krasnow; R S Hellman; M E Timins; B D Collier; T Anderson; A T Isitman
Journal:  Semin Nucl Med       Date:  1997-04       Impact factor: 4.446

Review 5.  Bone scan in metabolic bone diseases. Review.

Authors:  Saeid Abdelrazek; Piotr Szumowski; Franciszek Rogowski; Agnieszka Kociura-Sawicka; Małgorzata Mojsak; Małgorzata Szorc
Journal:  Nucl Med Rev Cent East Eur       Date:  2012-08-25

Review 6.  Tumoral calcinosis: pearls, polemics, and alternative possibilities.

Authors:  Kathryn M Olsen; Felix S Chew
Journal:  Radiographics       Date:  2006 May-Jun       Impact factor: 5.333

7.  Tumoral calcinosis: Diffuse multifocal form in hemodialysis patients. Two case reports.

Authors:  D Ibrahim Montasser; J Issouani; M Hassani; D Kabbaj
Journal:  Orthop Traumatol Surg Res       Date:  2017-05-30       Impact factor: 2.256

8.  Tc-MDP bone scintigraphy in a case with sporodical tumoral calcinosis.

Authors:  Tulay Kacar Guveli; Mehmet Mulazimoglu; Muge Oner Tamam; Cüneyt Tamam; Tarik Tatoglu; Tevfik Ozpacaci
Journal:  Indian J Nucl Med       Date:  2010-01

9.  Metabolic Bone Superscan in Carcinoma Breast with Occult Graves' Disease: Looking Beyond Skeletal Metastases.

Authors:  Ashwin Singh Parihar; Ashwani Sood; Tinu Thadiyananickal Lukose; Rajeev Kumar Seam; Bhagwant Rai Mittal
Journal:  Indian J Nucl Med       Date:  2018 Apr-Jun

10.  Facial Dysmorphism Due to Multiple Brown Tumors Secondary to Large Parathyroid Adenoma, Diagnosed on 99mTc-Sestamibi Parathyroid Scintigraphy.

Authors:  Ashwin Singh Parihar; Sanjay Bhadada; Anish Bhattacharya; Bhagwant Rai Mittal
Journal:  Indian J Nucl Med       Date:  2018 Jul-Sep
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.